Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 451 | 92 | 353 |
| Samples | 167 | 41 | 123 |
| Peptides | 144 | 33 | 110 |
Function
PPP1CA · Protein phosphatase 1 catalytic subunit alpha
The protein encoded by this gene is one of the three catalytic subunits of protein phosphatase 1 (PP1). This broadly expressed gene encodes the alpha subunit of the PP1 complex that associates with over 200 regulatory proteins to form holoenzymes which dephosphorylate their biological targets with high specificity. PP1 is a serine/threonine specific protein phosphatase known to be involved in the regulation of a variety of cellular processes, such as cell division, glycogen metabolism, muscle contractility, protein synthesis, and HIV-1 viral transcription. Increased PP1 activity has been observed in the end stage of heart failure. Studies suggest that PP1 is an important regulator of cardiac function and that PP1 deregulation is implicated in diabetes and multiple types of cancer. Three alternatively spliced transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Jul 2020].
Isoforms & Proteins
3 transcripts · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
Gene Properties
Recurrent Mutations
All 128 amino-acid changes on canonical ENST00000376745 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in PPP1CA · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in PPP1CA – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 5/40 12% | 0/0 0% |
| Endometrial Carcinoma | 1/42 2% | 7/612 1% |
| Bladder Carcinoma | 2/58 3% | 10/956 1% |
| Glioblastoma | 1/98 1% | 0/0 0% |
| Melanoma | 0/210 0% | 17/1899 1% |
| Colorectal Carcinoma | 9/143 6% | 17/3239 1% |
| Neuroendocrine Tumour | 2/154 1% | 3/577 1% |
| Gastric Carcinoma | 1/74 1% | 11/1809 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 4/810 0% |
| Ovarian Carcinoma | 2/109 2% | 4/998 0% |
| Germ Cell Tumour | 0/25 0% | 1/169 1% |
| Head and Neck Carcinoma | 1/85 1% | 7/1574 0% |
| Osteosarcoma | 1/45 2% | 0/166 0% |
| Non-Cancerous | 0/104 0% | 4/830 0% |
| Non-Small Cell Lung Carcinoma | 2/304 1% | 5/1390 0% |
| Other Solid Cancers | 2/94 2% | 4/1515 0% |
| Plasma Cell Myeloma | 0/44 0% | 1/305 0% |
| Breast Carcinoma | 6/144 4% | 3/3264 0% |
| Small Cell Lung Carcinoma | 1/9 11% | 1/752 0% |
| Kidney Carcinoma | 1/85 1% | 4/1862 0% |
| Esophageal Squamous Cell Carcinoma | 0/51 0% | 6/2550 0% |
| Cervical Carcinoma | 0/35 0% | 1/422 0% |
| Medulloblastoma | 0/0 0% | 1/450 0% |
| B-Cell Non-Hodgkins Lymphoma | 2/88 2% | 3/2534 0% |
| Prostate Carcinoma | 0/13 0% | 3/2105 0% |
| Esophageal Carcinoma | 0/23 0% | 1/769 0% |
| Hepatocellular Carcinoma | 0/46 0% | 3/2210 0% |
| Thyroid Gland Carcinoma | 0/45 0% | 2/1592 0% |
| Glioma | 0/52 0% | 2/2127 0% |
| B-Lymphoblastic Leukemia | 1/55 2% | 1/2640 0% |
Mutation Distribution
Where PPP1CA is mutated · all tissues, split by cell line vs tissue
How many mutations in PPP1CA were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 451 mutations in PPP1CA
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|